About the Pediatric Early Phase Clinical Trials Network (PEP-CTN)
NCI supports the Pediatric Early Phase Clinical Trials Network (PEP-CTN), a consortium of 42 leading children’s hospitals in the U.S., Canada, and Australia working to develop and evaluate promising new treatments for children and adolescents with cancer. Established in 2019, PEP-CTN designs and conducts pediatric early phase clinical trials, including phase 1 trials and pilot studies of novel agents or regimens to determine their tolerability. These early-phase studies provide evidence to determine whether promising treatments should proceed to later-phase clinical trials.
PEP-CTN builds on the work of the Children's Oncology Group (COG) Phase 1 Consortium and benefits from its close integration with COG, part of NCI’s National Clinical Trials Network. This connection provides access to established clinical trial operations, data management systems, scientific expertise, and resources that support efficient trial development and implementation. Sites are selected through a peer-review process to participate in PEP-CTN.
The PEP-CTN is supported by NCI cooperative agreement award UM1-CA228823.
Key Features of PEP-CTN:
- Scientific Prioritization: A centralized Agent Prioritization Committee evaluates promising treatments and research proposals to identify scientifically compelling opportunities for clinical testing.
- Coordinated Trial Development: Established clinical trial infrastructures support protocol development, regulatory review, trial activation, and centralized monitoring.
- Biological and Genomic Research: Molecular testing, biomarker studies, and other laboratory research help determine trial eligibility and improve understanding of how new treatments work.
- Collaboration across Pediatric Oncology: Investigators work with COG disease committees, academic research institutions, pharmaceutical companies, and other partners to advance promising therapies.
- Progression to Later-Phase Research: Close coordination with COG supports the advancement of promising therapies from early-phase testing to larger clinical trials.
Find a Clinical Trial or PEP-CTN Site
PEP-CTN clinical trials are conducted at participating children’s hospitals and research institutions. The availability of individual trials varies by institution, and eligibility depends on factors such as cancer diagnosis, prior treatment, and study requirements. Patients, families, and providers can explore network institutions and available clinical trials through the COG PEP-CTN website and NCI’s clinical trials search resources.
Submit a Research Proposal
Researchers may submit proposals for new agents and treatment approaches for consideration by the PEP-CTN Agent Prioritization Committee. The committee brings together PEP-CTN investigators, COG disease committees, other academic research teams, and pharmaceutical companies to identify and prioritize promising treatments for clinical evaluation. Investigators are encouraged to request a pre-review meeting before submitting a proposal.
Submit proposals using the PEP-CTN Agent Prioritization Committee proposal form. Questions and pre-review meeting requests can be addressed to: NCI-PEP-CTN@nih.gov.
Advancing Early-Phase Pediatric Brain Tumor Clinical Trials Through the PEP-CTN
In 2026, NCI expanded PEP-CTN’s role to give it primary responsibility within NCI’s infrastructure of clinical trials networks to develop early-phase clinical trials for children with brain tumors. Early phase pediatric brain tumor trials were conducted through the NCI-funded Pediatric Brain Tumor Consortium (PBTC), a smaller network of 16 sites. Although PBTC made important contributions, patient enrollment and new trial activation have declined substantially in recent years. NCI transitioned this research to PEP-CTN to accelerate patient accrual, strengthen NCI’s ability to develop and conduct early-phase pediatric brain tumor trials, and expand opportunities for families through its 42 sites. This decision reflects NCI’s commitment to ensuring that promising scientific ideas are translated into high-quality clinical trials that enroll patients in a timely manner and generate meaningful research results.
- In 2026, NCI secured funding for PEP-CTN by approximately $4 million above the previous committed level to support its expanded role in conducting early-phase clinical trials for children with brain tumors. This increased funding will continue through 2029 to support the additional research costs associated with an expanded portfolio of early-phase brain tumor trials and the now-completed transition of the former PBTC clinical trial portfolio. It will also support administrative modernization and new approaches to pediatric cancer research, including the application of Super Intelligence (SI), to improve trial efficiency and patient accrual.
The expanded PEP-CTN:
- Supports efficient clinical trial development and conduct through close integration with COG to provide greater abilities in data management, information technology, training, and clinical trial resources.
- Expands clinical trial opportunities to PEP-CTN’s 42 sites, compared with PBTC’s 16, offering families greater access to early-phase brain tumor trials.
- Works with patients and families, researchers, advocates, and other partners to expand clinical trial opportunities for children with brain tumors.
- Provides a clear pathway for new brain tumor clinical trial proposals through a new committee that meets monthly to consider new agents and treatments from researchers around the country for evaluation.
- Strengthens its pediatric neuro-oncology expertise through increased and dedicated leadership participation by neuro-oncologists with experience in early-phase drug development in PEP-CTN's scientific review and protocol development processes.